1. subject is intubated. 2. subject is currently taking immunomodulators or anti-rejection drugs. 3. subject has been administered an immunomodulating biologic drug within 60 days of baseline. 4. subject is in septic shock defined as persistent hypotension requiring vasopressors to maintain mean arterial pressure (map) of 65 mm hg or higher and a serum lactate level greater than 2 mmol/l (18 mg/dl) despite adequate volume resuscitation. 5. subject has received any live attenuated vaccine, such as varicella-zoster, oral polio, or rubella, within 3 months prior to the baseline visit.

1. subject is intubated. 2. subject is currently taking immunomodulators or anti-rejection drugs. 3. subject has been administered an immunomodulating biologic drug within 60 days of baseline. 4. subject is in septic shock defined as persistent hypotension requiring vasopressors to maintain mean arterial pressure (map) of 65 mm hg or higher and a serum lactate level greater than 2 mmol/l (18 mg/dl) despite adequate volume resuscitation. 5. subject has received any live attenuated vaccine, such as varicella-zoster, oral polio, or rubella, within 3 months prior to the baseline visit.

subject is intubated. subject is currently taking immunomodulators or anti-rejection drugs. subject has been administered an immunomodulating biologic drug within 60 days of baseline. subject is in septic shock defined as persistent hypotension requiring vasopressors to maintain mean arterial pressure (map) of 65 mm hg or higher and a serum lactate level greater than 2 mmol/l (18 mg/dl) despite adequate volume resuscitation. subject has received any live attenuated vaccine, such as varicella-zoster, oral polio, or rubella, within 3 months prior to the baseline visit.

subject is intubated. subject is currently taking immunomodulators or anti-rejection drugs. subject has been administered an immunomodulating biologic drug within 60 days of baseline. subject is in septic shock defined as persistent hypotension requiring vasopressors to maintain mean arterial pressure (map) of 65 mm hg or higher and a serum lactate level greater than 2 mmol/l (18 mg/dl) despite adequate volume resuscitation. subject has received any live attenuated vaccine, such as varicella-zoster, oral polio, or rubella, within 3 months prior to the baseline visit.

1. subject is intubated. 2. subject is currently taking immunomodulators or anti-rejection drugs. 3. subject has been administered an immunomodulating biologic drug within 60 days of baseline. 4. subject is in septic shock defined as persistent hypotension requiring vasopressors to maintain mean arterial pressure (map) of 65 mm hg or higher and a serum lactate level greater than 2 mmol/l (18 mg/dl) despite adequate volume resuscitation. 5. subject has received any live attenuated vaccine, such as varicella-zoster, oral polio, or rubella, within 3 months prior to the baseline visit.

1. subject is intubated. 2. subject is currently taking immunomodulators or anti-rejection drugs. 3. subject has been administered an immunomodulating biologic drug within 60 days of baseline. 4. subject is in septic shock defined as persistent hypotension requiring vasopressors to maintain mean arterial pressure (map) of 65 mm hg or higher and a serum lactate level greater than 2 mmol/l (18 mg/dl) despite adequate volume resuscitation. 5. subject has received any live attenuated vaccine, such as varicella-zoster, oral polio, or rubella, within 3 months prior to the baseline visit.